Abstract Novel Triclosan mimic diphenyl ether derivatives 4a-k were designed and synthesized with lipophilicity considerably lesser than that of Triclosan. The binding mode of the compounds at the active site of enoyl-ACP reductase was analysed using docking method. The syntheses were carried out with one-pot reductive amination reaction and were characterized by spectral techniques. The synthesized compounds were evaluated for their in vitro antitubercular activity against Mycobacterium tuberculosis H37Rv strain by Microplate Alamar Blue assay. Compounds 4h and 4j were the most active compounds with MIC equal to 25 lg/mL against M. tuberculosis H37Rv strain. All compounds were also examined for their cytotoxic potential against VERO and HepG2 cell lines and were safe even at 300 lg/mL. Log P of all the synthesized compounds was evaluated by RPHPLC and was significantly lesser than Triclosan. 
Introduction
Tuberculosis is a significant medical problem worldwide, particularly in the developing world, where up to 80% of the population are thought to be infected by the bacterium Mycobacterium tuberculosis in either latent or active form. It is responsible for nearly 3 million deaths worldwide every year (Bloom and Murray, 1992, Organisation, 2013) . While tuberculosis is treatable through antibiotic regimes, the currently used frontline antimycobacterial drugs, isonicotinylhydrazine (INH) and rifampicin (RMP), have been used in the treatment of tuberculosis for at least 50 years. Long treatment times tend to lead to poor patient treatment compliance, which coupled with the lack of successful development of new classes of antimycobacterial drugs has led to the emergence of drug resistant strains of M. tuberculosis. These include multidrug resistant TB (MDR-TB), extensively drug resistant TB (XDR-TB) and, more recently, totally drug resistant TB (TDR-TB) which is resistant to all currently available antibiotics. Increase in the incidence of TB in the recent years has also been attributed to the co-infection with HIV (El Sayed et al., 2000) . This underlines the urgent need to develop new classes of antimycobacterial drugs.
To address the problems of ever increasing resistance, serious side effects of some anti-TB drugs, long term treatment, incompatibility of antiretroviral therapies for current TB regimen, research activities to develop novel anti-TB agents with stronger efficacy have become an urgent priority. Many studies targeting the mycobacterial cell wall and particularly the biosynthesis of mycolic acid have been reported. InhA [also known as Enoyl Acyl Carrier protein Reductase (Mtb ENR)] is an essential enzyme of mycolic acid biosynthesis pathway. This pathway is involved in the synthesis of type II fatty acids required for the formation of the mycobacterial cell wall and therefore, considered as a good target (Bloch, 1977; Marrakchi et al., 2008) . The major advantage of this target is that, it is present in the Mycobacterium but is absent in human. Moreover, InhA has already been known as the molecular target of the frontline antitubercular drugs isoniazid and ethionamide (ETA) (Banerjee et al., 1994; Wang et al., 2007) . Well-known local antibacterial agent Triclosan (1) has been reported to be a specific InhA inhibitor (Levy et al., 1999) . Unfortunately, Triclosan has the disadvantage such as higher lipophilicity and moderate MIC (12.5 lg/ml) (Dann and Hontela, 2011) . Hence major attention has been put forward to develop a druggable Triclosan analogue with improved antitubercular activity. The study reported herein concerns our efforts to optimize the Triclosan scaffold to decrease its lipophilicity without compromising the antitubercular activity and cytotoxicity. We have also attempted the structure based drug design technique to explore the structural alternates at the position 4 of ring-A of Triclosan to sustain the molecular interactions of a typical InhA inhibitor at the receptor binding pocket.
Materials and methods

Molecular modeling
A library of Triclosan (1) analogues was prepared considering Lipinski's drug-like parameters [molecular weight 6 500, CLog P 6 5, hydrogen bond donors 6 5 and hydrogen bond acceptors 6 10]. Structures of designed diphenyl ethers were drawn and converted to 3D structures. Generation of ionization state (through Epik) of the ligands was done using Ligprep tool of Schrodinger-2011. OPLS-2005 force field was used for the energy minimization of 3D structures of the ligands. The X-ray structure of M. tuberculosis ENR (pdb 1P45) was used in all the docking experiments. The InhA protein was optimized through Protein preparation wizard of Schrodinger-2011. Protein was pre-processed by assigning bond order, adding hydrogens and treating disulfide. Water molecules within 5 Å of the binding site were removed. Hydrogen bond was assigned by exhaustive sampling and energy was minimized to RMSD 0.30 Å by OPLS-2005. Receptor grid was generated around the co-crystallized ligand (Triclosan) in Schrodinger-2011 suit by using default parameters. Ligand was excluded from the protein, and it was confined to the enclosing box at the centroid. The grid was generated to fit the ligands similar in size to Triclosan. Flexible docking study was conducted with standard precision (SP) Halgren et al., 2004) . Epik state penalty was added to the docking score. Docking was limited to the ligands having <300 atoms and <50 rotable bonds. Van der Waal radii of the ligand atoms were scaled to 0.8 and the partial charge cutoff was kept less than 0.15. The position of ligand was kept at the center of a 10 Å docking sphere. Default settings were used in Glide for all dockings. At the beginning, co-crystallized ligand (Triclosan) was extracted from the optimized protein and redocked to probe the RMSD and docking parameters. Then all the compounds were docked with the Mtb InhA protein at the Triclosan binding site. Then all ligand docking results from SP docking were studied.
Synthesis
All the chemicals used as starting materials and catalysts in this study were purchased from Aldrich Chemical Co., India, Spectrochem Ltd. India, TCI Chemicals, India, and Himedia, India. All the solvents used were obtained from S.D. Fine Chemicals Ltd, India, and Merck, India. Column chromatography was carried out on 100-200 mesh silica gel. Progress of the reactions was monitored by TLC using Aluminum backed sheets of silica gel 60 F24 (Merck, India). Melting points were recorded with a laboratory melting point apparatus and are uncorrected.
1 H NMR and
13
C NMR spectra were recorded on NMR Spectrometer (AV400-400 MHz High Resolution Multinuclear FT-NMR Spectrometer, Bruker, USA) using DMSO-d 6 as the solvent. Mass spectroscopy was performed using LC-MS (Q-TOF LC/MS, Agilent 6520 series, USA) and GC-MS (GCMS-QP5050A, Shimadzu, Japan). IR spectrum was obtained using FT IR Spectrophotometer (IR Affinity-1, Shimadzu, Japan) using KBr pellets.
3-Methoxy-4-phenoxybenzaldehyde (2)
To the stirred solution of vanillin (5 g, 32.89 mmol) in anhydrous dichloromethane (60 mL), activated molecular sieves (4 Å , 2.5 g), phenylboronic acid (6.01 g, 49.33 mmol), copper (II) acetate (8.96 g, 49.33 mmol) and anhydrous pyridine (5.19 g, 64.78 mmol) were added successively. The resulting suspension was stirred at 25-27°C for 72 h. Progress of the reaction was monitored by TLC, using hexane:ethyl acetate (8:2) as mobile phase. After the completion of reaction (72 h), the reaction mixture was diluted with dichloromethane (40 mL) and filtered under vacuum. The filtrate was washed with dilute aqueous hydrochloric acid solution (2 M, 50 mL), followed by water (50 mL), dried over anhydrous MgSO 4 and evaporated under vacuum. The crude compound obtained was purified by column chromatography over silica 100-200 with hexane:ethyl acetate (8:2) as the mobile phase to afford the target compound. Yield = 5 g (67%); mp = 40-42°C; R f = 0.83 (hexane: ethyl acetate = 8:2); kmax = 275.2 nm (MeOH).
3-Hydroxy-4-phenoxybenzaldehyde (3)
To the solution of compound 4 (3 g, 13.16 mmol) in glacial acetic acid (50 mL), HBr (48%v/v, 12 mL) was added and the solution was refluxed at 110-112°C for 24 h. Progress of the reaction was monitored by TLC, using hexane:ethyl acetate (8:2) as mobile phase. The reaction mixture was cooled, poured into water and extracted with ethyl acetate (3 Â 50 mL). The organic layers were combined and washed with saturated NaHCO 3 solution, dried over anhydrous 
General procedure for the synthesis of compounds 4a-k
To the stirred solution of amine (1.12 mmol) in Dichloroethane (5 mL), compound 2 (0.2 g, 0.93 mmol), NaBH 3 CN (0.058 g, 0.93 mmol) and glacial acetic acid (2 drops) were added and stirring was continued at room temperature for 12 h. Progress of the reaction was monitored by TLC, using chloroform:methanol (9:1) as mobile phase. After completion of reaction, the solvent was evaporated; water was added, and extracted with ethyl acetate (3 Â 20 mL). The organic layers were combined and washed with sodium bicarbonate solution, dried over anhydrous MgSO 4 and evaporated under vacuum. The crude product obtained was purified by column chromatography over silica 100-200 with chloroform:methanol (9:1) as the mobile phase to afford the target compound.
2.2.3.1.
5-Butylaminomethyl-2-phenoxy-phenol (4a). Yield = 0.160 g (63%); mp = 104-106°C; R f = 0.41 (chloroform:methanol = 9:1); kmax = 276 nm (MeOH); IR (KBr, cm À1 ) = 3525, 3305, 2945, 2846, 1597, 1514, 1487, 1292, 1246, 1211, 1159; 1 H NMR (400 MHz, DMSO-d 6 ): 9.39 (s, 1H), 7.28 (t, J = 7.8 Hz, 2H), 7.00-6.95(m, 2H), 6.88(d, J = 8 Hz, 1H), 6.81(d, J = 8 Hz, 2H), 6.76(d, J = 8 Hz, 1H), 5.88(s, 1H),1.47-1.27(m, 6H), 0.86(t, J = 12 Hz, 3H), 13 C NMR (100.62 MHz, DMSO-d 6 ): 13.92, 19.95, 29.87, 31.49, 39.48, 45.65, 48.32, 52.51, 116.75, 119.04, 121.45, 138.14, 140.86, 149.02, 158.16 2.2.3.3. 5-Allylaminomethyl-2-phenoxy-phenol (4c). Yield = 0.165 g (69%); mp = 84-86°C; R f = 0.37 (chloroform:methanol = 9:1); kmax = 276 nm (MeOH); IR (KBr, cm À1 ) = 3388, 3288, 2929, 2858, 1583, 1494, 1458, 1261, 1213, 1161 39.70, 50.89, 51.74, 115.90, 116.73, 117.89, 119.02, 126.63, 132.15, 138.29, 140.82, 158.17 30.41, 33.32, 39.50, 40.13, 45.30, 50.15, 60.76, 116.20, 118.03, 121.40, 129.52, 141.86, 149.04, 157.88 82, 28.61, 32.14, 34.00, 39.5, 5083, 62.50, 116,00, 119.72, 121.46, 140.92, 149.00, 158.19 ; GCMS(EI, m/ z) 297 (M) + .
2.2.3.8. 5-(4-Aminomethyl-piperidin-1-ylmethyl)-2-phenoxyphenol (4h). Yield = 0.220 g (79%); R f = 0.71 (chloroform: methanol = 8:2); kmax = 278 nm (MeOH); IR (KBr, cm À1 ) 3622, 3589, 3452, 3425, 3398, 2933, 2368, 1589, 1519, 1467, 1300, 1220, 1181 29.62, 38.86, 39.49, 43.87, 49.79, 50.26, 52.57, 61.89, 115.99, 117.40, 119.74, 121.48, 129.48, 135.79, 141.18, 149.08, 158 (Leonard et al., 2008; Ryan et al., 1995) . Frozen stock culture suspension of M. tuberculosis H37Rv (ATTCC 27294) from Lowenstein-Jensen slants in complete 7H9 broth was vortexed, adjusted to a turbidity equivalent to that of a 1 McFarland standard (3 Â 10 8 cfu/mL). It was further diluted with media-I (Difco Middlebrook 7H9, Bactocasitone, Difcoglycerol and OADC) to a concentration of 2 Â 10 5 cfu/mL and used as inoculum in the MABA assay. Test samples and standard compounds (Isoniazid and Rifampicin) were dissolved in DMSO and sterilized by filtering through syringe driven filters (0.22 lm, 13 mm, Himedia, India) to prepare stock solutions of concentration 20,000 lg/mL. The stock solutions were diluted serially with media-II (Middlebrook 7H9 broth, Bactocasitone, Difco polysorbate-80 and OADC) in a 96 deep well plate to afford working solutions of 4Â strength. Outer perimeter wells of the 96 well plates were filled with sterile deionized water to prevent dehydration in test wells during incubation. Media-II (100 lL) was added to each well of the 96 well plate and twofold serial dilutions of the test compounds was done directly on the plate by using a multichannel micropipette. Inoculum (100 lL, 2 Â 10 5 cfu/mL) was added to each well, yielding a final testing volume of 200 lL and the final drug concentrations tests were 3.125-100 lg/mL. Isoniazid and Triclosan were used as standard and DMSO as blank. Positive control (only inoculum) and negative control (only media) were also applied in the plate to minimize the error. Then the plate was sealed (breathseal) and incubated at 37°C under aeration. On the seventh day of incubation, 12.5 lL of 20% Tween-80 and 20 lL of Alamar blue were added to each well of the plate and incubated for another 24 h at 37°C. A change in color from blue to pink was considered as the growth of the Mycobacterium at that concentration of the drug. For better interpretation of the results, the color was compared to the color present in the growth control wells. The MICs were defined as the lowest concentration of drug that inhibited bacterial growth.
In vitro cytotoxicity
Synthesized compounds were assessed for their in vitro safety profile against Vero and HepG2 cells using MTT assay. The cellular conversion of MTT [3-(4,5-dimethylthiazo-2-yl)-2,5-d iphenyl-tetrazolium bromide] into a formazan product was used to evaluate the cytotoxic effect of the synthesized compounds against a mammalian Vero cell line from the kidney of African Green monkey (Ammerman et al., 2008) . Outer perimeter wells of the 96 well plates were filled with sterile deionized water to prevent dehydration in test wells during incubation. Stock solution of test samples was diluted with DMEM (without FBS) in a 96 deep well plate to afford working solutions of concentrations 300, 250, 200, 150, 100, 100 and 50 lg/mL. Final concentration of DMSO was kept 60.1%. 100 lL of test samples was added to each wells containing monolayer of Vero cells (10 4 cells/well) in a 96-well plate. The plate was incubated at 37°C with 5% of CO 2 inside an incubator. Positive control (only inoculum) and negative control (only media) were also maintained in the plate. After 72 h of incubation, the supernatant was removed from the wells. 50 lL of MTT reagent (2 mg/mL) was added to the wells in dark and incubated at 37°C for 4 h. 50 lL of sterile DMSO (filtered through 0.22 lm syringe filter) was added to each well to dissolve the formazan crystals formed by the cells. The plate was transferred to an incubator and kept at 37°C for 2 h. Optical density (OD) of the wells was measured at 540 nm using Elisa Reader. The CC 50 values were determined using a curve-fitting program.
In vitro hepatotoxicity
MTT assay against HepG2 cells was performed by following the method described for in vitro cytotoxicity screening against Vero cell line. In case of HepG2 cells, 5 Â 10 3 cells/well was added and MTT was added after 24 h of incubation.
Optical Density (OD) readings from each well were entered into the equations shown below to determine % Cell Viability and % Cell Inhibition.
% Cell Viability ¼ ðOptical Density of Test =Optical Density of ControlÞ Â 100 % Cell Inhibition ¼ 100 À % Cell Viability
Determination of log P
Reverse phase HPLC method was applied to determine the log P (lipophilicity) of the compounds (Ong et al., 1996; Poole and Poole, 2003) . All the chromatographic runs were conducted on HPLC (Shimadzu, Japan) at room temperature using ODS-4 (Intersil ODS-4, 5 lm, 4.6 Â 150 mm, GL Science Inc., Japan) column and UV-Visible detector. Numerical analysis and data processing were done using Lab solution-2013 software. 3-Morpholinopropane-1-sulfonic acid (MOPS, 4.18 g) was added to 900 mL octanol saturated MilliQ water, and the volume was made up to 1 L. pH of the buffer was adjusted to 7.4. A mixture of methanol (0.25%v/v octanol) and buffer at the ratio of 60:40, 65:45 and 70:30, was used to elute the test sample. 5 lL of the sample was injected, and flow rate was kept at 1 mL/min. Signal was detected at kmax 270 nm. Sample run time was kept in between 15 min. and 1 h. Capacity factor (k 0 ) was calculated for each run by using the equation given below (Gocan et al., 2006) .
where t R is the retention time of sample, t 0 is the retention time of blank (methanol). A graph was plotted by taking log k 0 (y axis) and % methanol (3-4% concentrations) (x-axis). The logarithm of k 0 was extrapolated to a 0% concentration of methanol in the graph. Log k 0 at 0% methanol was calculated from the regression equation (R 2 = 0.99) generated from the graph to determine log P of the compounds.
Results and discussion
Rationale of drug design and analysis of the docking results
Triclosan is highly lipophilic with log P value of 5.56. The chlorine functionalities in the molecule contribute significantly to the log P value. The objective of the present work is to develop diphenyl ether derivatives with lower lipophilicity. Chloro substitutions in ring-B of Triclosan are reported to be involved in unfavorable steric interactions with the enzyme, and their deletion from the scaffold increases the affinity 7-fold (Sivaraman et al., 2004) . Hence diphenyl ether derivatives without chloro substitutions in ring-B and with hydrophilic substituents at the 4th position of ring-A of diphenyl ether ring (Fig. 1) were designed. These modifications aim to decrease the inherent lipophilicity of Triclosan without compromising its orientation and catalytic interactions at the receptor (Mycobacterial Enoyl acyl carrier protein reductase [Mtb ENR]) binding site.
Compounds that satisfied Lipinski's parameter of druglikeness were docked against Mtb ENR. Molecular docking results revealed that compounds 4a-k overlaid perfectly with that of Triclosan (Figs. 2 and 3) . Furthermore, docking studies suggested the formation of hydrogen-bonding interactions between phenolic -OH and ether oxygen of our compounds with Tyr-158 and NAD-350 of Mtb ENR (Table 1 ). The hydrogen bonding network was consistent throughout our compounds, and this feature is reported to be a conserved feature among all the InhA-inhibitor complexes, including Triclosan (He et al., 2006) . Hence the core features of Triclosan, such as diphenyl ether ring and the phenolic -OH in ring-A were kept intact in all the designed analogues.
Compounds with long chain aliphatic substituents (compounds 4a, 4c and 4k) possessed low docking scores (Table 1) , indicating unfavorable orientations of the analogues at the target binding site.
Chemistry
The synthetic route employed is shown in Fig. 4 . Lam-Cham O-arylation of vanillin with phenyl boronic acid gave 3-methoxy-4-phenoxybenzaldehyde (compound 2) (Gillmore et al., 2003; Tipparaju et al., 2008) . HBr-AcOH assisted O-demethylation (Chhibber et al., 2006) of compound 2 afforded 3-hydroxy-4-phenoxy benzaldehyde (Compound 3) which was further appended with less lipophilic heterocycles through reductive amination (Abdel-Magid and Mehrman, 2006) technique to give the desired compounds 4a-k.
Biological evaluation
Compounds 4a-k was evaluated for antitubercular activity against M. tuberculosis H 37 Rv using MABA technique (Table 2 ). Safety profiles of the synthesized compounds are also presented in Table 2 . Compounds with n-butyl amine side chain (4a) and allylamine side chain (4c) demonstrated poor activity (MIC = 100 lg/mL), but when they were replaced with tert-butyl amine substituent, further reduction in the activity was observed (4b, MIC > 100 lg/mL). In general, it was observed that the addition of long aliphatic chain substituents at A-ring of diphenyl ether scaffold results in diminished antitubercular activities. Introduction of pyrrolidine at the 4th position of A-ring of diphenyl ether through a methylene bridge resulted in improvement of activity (4d, MIC = 50 lg/mL). However, this result was not sustained with a piperidine substituent (4e, MIC = 100 lg/mL). Introduction of a polar hydroxyl group at the 4th position of the piperidine ring of compound 4e increased the antiTB activity by twofold. But this activity was weakened with the incorporation of comparatively nonpolar methyl group in place of -OH group of 4f. When the methyl group of piperidine in compound 4g was replaced by a methyl amino group, excitingly, there was improvement of activity (4h MIC = 25 lg/mL). This increase in antitubercular activity was in line with the increased lipophilicity (log P = 3.02) of compound 4h. When the piperidine substituent of compound 4e was replaced with morpholine, obtained compound 4i exhibited antiTB activity at 100 lg/mL. Introduction of thiomorpholine enhanced the activity dramatically to 25 lg/mL without much increase in the lipophilicity. But this promising antiTB activity of 4j was not sustained with the introduction of N-methyl piperazine which led to a drastic loss of activity. Overall SAR of the scaffold suggests that there is a size limit requirement for substituents at the 4th position of A-ring of diphenyl ether pharmacophore to attain the optimal activity. Although the MIC results of our most active compounds (4h and 4j, MIC = 25 lg/mL), were twofold less than the MIC of parent Triclosan (MIC = 12.5 lg/mL), their log P values were found to considerably lower than Triclosan (Table 2) . Notably, all the synthesized Triclosan analogues displayed much lower toxicity in the MTT assay against epithelial cells (Vero) and hepatocytes (HepG2) than Triclosan. 
Conclusions
A series of Triclosan analogues has been designed, synthesized and evaluated for antitubercular activity against M. tuberculosis H 37 Rv. Most of the compounds showed weak to moderate antitubercular activity. Most promising compounds 4j and 4h exhibited MIC at 25 lg/mL against M. tuberculosis H 37 Rv. All of our synthesized compounds showed an excellent safety profile and lesser lipophilicity than the Triclosan. However, more experiments are needed to learn the structural requirements for improvement of antitubercular activity of this scaffold. Further studies are under progress.
